Responses
Clinical/translational cancer immunotherapy
Original research
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Compose a Response to This Article
Other responses
No responses have been published for this article.